SEC Form 4 · accession 0001209191-15-061927
KYNTRA BIO, INC. · KYNB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Pat Cotroneo
Officer — VP, Finance and CFO
Period of report
Jul 17, 2015
Accepted (ET)
Jul 21, 2015 · 6:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000921299
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jul 17, 2015 | S | 5,381 | $23.23 | D | 105,818 | D | |
| Common Stock | Jul 20, 2015 | M | 2,500 | $2.35 | A | 108,318 | D | |
| Common StockF1 | Jul 20, 2015 | S | 2,500 | $24.00 | D | 105,818 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $2.35 | Jul 20, 2015 | M | 2,500 | D | — | Mar 12, 2018 | Common Stock | 2,500 | 5,500 | D |
Explanation of responses
- F1Shares sold pursuant to a 10b5-1 plan.
- F2The shares were sold at prices between $22.98 and $23.69. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3Fully vested.